Evanthia Roussos Torres

Title(s)Assistant Professor of Medicine
AddressNOR 6421 NTT
Health Sciences Campus
Los Angeles CA 90089
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Roussos Torres received a BS in Microbiology, Immunology and Molecular Genetics and a BA in World Arts and Cultures with a concentration in Dance from the University of California at Los Angeles (UCLA). She then went on to receive her combined MD/PhD from the Medical Scientist Training Program at the Albert Einstein College of Medicine in New York. Her PhD focused on novel markers of breast cancer metastasis in the lab of Dr. John Condeelis. Dr. Roussos Torres then completed her internal medicine residency at the Hospital of the University of Pennsylvania. She began her hematology/ oncology fellowship training at the University of Pennsylvania and following the completion of her major clinical requirements, she transferred to Johns Hopkins University to pursue her research interests in cancer immunology under the mentorship of Dr. Elizabeth Jaffee. Her enthusiasm for both basic and translational cancer research led to her being awarded the first MacMillan fellowship from Johns Hopkins, which helped launch her career in laboratory translational research. Dr. Roussos Torres graduated from fellowship and began her faculty career as an Assistant Professor at Johns Hopkins University and is now an Assistant Professor at the University of Southern California she leads her own lab and works collaboratively with other physicians and physician scientists to continue her work in immune-oncology with a specific interest in breast cancer.

    A long-term goal of immunotherapy is to significantly prolong the lives of patients with breast cancer without the toxicity of traditional chemotherapy. Unlike chemotherapy, the beneficial effects of immunotherapy continue to work even after treatment has stopped. These lasting effects translate to years of improved quality of life and disease stability even in cases where breast cancer has spread to other organs in the body. One hurdle that needs to be overcome is to broaden the approval of immunotherapy to include more patients diagnosed with breast cancer. To help bring this life saving therapy to more patients, we need to better understand how different sub-sets of immune cells in the tumor microenvironment contribute to the sub-optimal immune response to checkpoint inhibition. Dr. Roussos Torres’ lab investigates suppressor cells such as myeloid derived suppressor cells, and T regulatory cells as well as other types of immune cells such as tumor associated macrophages and how these cells function to prevent immune activation. The work in the lab aims to understand mechanisms of suppression so that we can design novel therapeutic combinations that will overcome these suppressive signals and improve response to immunotherapy in breast cancer.

    Dr. Roussos Torres is very passionate about her research as well as her care of patients with cancer and training of the fellows to become compassionate and knowledgeable physicians. She is driven to make memorable contributions to the field of cancer research given her personal experience advocating for her mother who died from metastatic breast cancer in 2016. Dr. Roussos Torres felt passionate about having an impact on the field of breast cancer prior to her mother’s diagnosis but learning about the devastation of metastatic disease as the family member of a patient provided a different perspective and drive for novel treatment options.

    Dr. Roussos Torres loves her work but also prioritizes her family life; her husband Dr. Stephen Torres is an orthopaedic surgeon, specializing in sports medicine and together they have three sons, Owen (5 years old), James (3 years old) and Luke (1 year old) who fill their life with joy and make every day a wonder! The Torres family also has two Chesapeake Bay retrievers, Jackson (9 years old) and Emma (6 years old) who greatly contribute to our active lifestyle! Dr. Roussos Torres enjoys traveling, eating out at new restaurants and road biking! Dr. Roussos Torres grew up in Santa Monica and is so happy to have returned to Southern California where she and her husband can raise their family near her own siblings, their families, and her father who still resides here.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Phase 1 Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). Clin Cancer Res. 2021 Jun 16. Roussos Torres ET, Rafie CI, Wang C, Lim D, Brufsky AM, LoRusso PM, Eder JP, Chung V, Downs M, Geare M, Piekarz RL, Streicher H, Anforth L, Rudek MA, Zhu Q, Besharati S, Cimino-Mathews A, Anders RA, Stearns V, Jaffee EM, Connolly RM. PMID: 34135021.
      View in: PubMed   Mentions:    Fields:    
    2. Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response. Front Mol Biosci. 2021; 8:674558. Goode EF, Roussos Torres ET, Irshad S. PMID: 34141724.
      View in: PubMed   Mentions:
    3. Clocking cancer: the circadian clock as a target in cancer therapy. Oncogene. 2021 May; 40(18):3187-3200. Battaglin F, Chan P, Pan Y, Soni S, Qu M, Spiller ER, Castanon S, Roussos Torres ET, Mumenthaler SM, Kay SA, Lenz HJ. PMID: 33846572.
      View in: PubMed   Mentions:    Fields:    
    4. Adopting an alternative structure for clinical trials in immunotherapy. Expert Rev Anticancer Ther. 2021 Apr; 21(4):373-375. Roussos Torres ET, Epstein AL. PMID: 33435760.
      View in: PubMed   Mentions:    Fields:    
    5. Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. JCO Oncol Pract. 2020 Oct; 16(10):665-674. Sheng JY, Santa-Maria CA, Mangini N, Norman H, Couzi R, Nunes R, Wilkinson M, Visvanathan K, Connolly RM, Roussos Torres ET, Fetting JH, Armstrong DK, Tao JJ, Jacobs L, Wright JL, Thorner ED, Hodgdon C, Horn S, Wolff AC, Stearns V, Smith KL. PMID: 32603252.
      View in: PubMed   Mentions:
    6. Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. Oncoimmunology. 2020 05 14; 9(1):1760685. Mirando AC, Patil A, Rafie CI, Christmas BJ, Pandey NB, Stearns V, Jaffee EM, Roussos Torres ET, Popel AS. PMID: 32923118.
      View in: PubMed   Mentions:
    7. Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-16. Sharma P, Connolly RM, Roussos Torres ET, Thompson A. PMID: 32315235.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. Front Bioeng Biotechnol. 2020; 8:141. Wang H, Sové RJ, Jafarnejad M, Rahmeh S, Jaffee EM, Stearns V, Roussos Torres ET, Connolly RM, Popel AS. PMID: 32158754.
      View in: PubMed   Mentions:
    9. Differential Variation Analysis Enables Detection of Tumor Heterogeneity Using Single-Cell RNA-Sequencing Data. Cancer Res. 2019 10 01; 79(19):5102-5112. Davis-Marcisak EF, Sherman TD, Orugunta P, Stein-O'Brien GL, Puram SV, Roussos Torres ET, Hopkins AC, Jaffee EM, Favorov AV, Afsari B, Goff LA, Fertig EJ. PMID: 31337651.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    10. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity. Cancer Immunol Res. 2019 03; 7(3):428-442. Ma HS, Poudel B, Torres ER, Sidhom JW, Robinson TM, Christmas B, Scott B, Cruz K, Woolman S, Wall VZ, Armstrong T, Jaffee EM. PMID: 30642833.
      View in: PubMed   Mentions: 30     Fields:    Translation:AnimalsCells
    11. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res. 2018 12; 6(12):1561-1577. Christmas BJ, Rafie CI, Hopkins AC, Scott BA, Ma HS, Cruz KA, Woolman S, Armstrong TD, Connolly RM, Azad NA, Jaffee EM, Roussos Torres ET. PMID: 30341213.
      View in: PubMed   Mentions: 35     Fields:    Translation:AnimalsCells
    12. N-WASP-mediated invadopodium formation is involved in intravasation and lung metastasis of mammary tumors. J Cell Sci. 2012 Feb 01; 125(Pt 3):724-34. Gligorijevic B, Wyckoff J, Yamaguchi H, Wang Y, Roussos ET, Condeelis J. PMID: 22389406.
      View in: PubMed   Mentions: 116     Fields:    Translation:AnimalsCells
    13. Setup and use of a two-laser multiphoton microscope for multichannel intravital fluorescence imaging. Nat Protoc. 2011 Sep 08; 6(10):1500-20. Entenberg D, Wyckoff J, Gligorijevic B, Roussos ET, Verkhusha VV, Pollard JW, Condeelis J. PMID: 21959234.
      View in: PubMed   Mentions: 60     Fields:    Translation:Animals
    14. Chemotaxis in cancer. Nat Rev Cancer. 2011 Jul 22; 11(8):573-87. Roussos ET, Condeelis JS, Patsialou A. PMID: 21779009.
      View in: PubMed   Mentions: 313     Fields:    Translation:HumansAnimalsCells
    15. Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. J Cell Sci. 2011 Jul 01; 124(Pt 13):2120-31. Roussos ET, Balsamo M, Alford SK, Wyckoff JB, Gligorijevic B, Wang Y, Pozzuto M, Stobezki R, Goswami S, Segall JE, Lauffenburger DA, Bresnick AR, Gertler FB, Condeelis JS. PMID: 21670198.
      View in: PubMed   Mentions: 95     Fields:    Translation:AnimalsCells
    16. Mena invasive (Mena(INV)) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEM. Clin Exp Metastasis. 2011 Aug; 28(6):515-27. Roussos ET, Goswami S, Balsamo M, Wang Y, Stobezki R, Adler E, Robinson BD, Jones JG, Gertler FB, Condeelis JS, Oktay MH. PMID: 21484349.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCells
    17. Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors. Breast Cancer Res. 2010; 12(6):R101. Roussos ET, Wang Y, Wyckoff JB, Sellers RS, Wang W, Li J, Pollard JW, Gertler FB, Condeelis JS. PMID: 21108830.
      View in: PubMed   Mentions: 43     Fields:    Translation:AnimalsCells
    18. AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res. 2010 Oct 01; 70(19):7360-4. Roussos ET, Keckesova Z, Haley JD, Epstein DM, Weinberg RA, Condeelis JS. PMID: 20823151.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    19. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res. 2009 Dec 01; 69(23):8868-76. Pang H, Flinn R, Patsialou A, Wyckoff J, Roussos ET, Wu H, Pozzuto M, Goswami S, Condeelis JS, Bresnick AR, Segall JE, Backer JM. PMID: 19903845.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansAnimalsCells
    20. A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell. 2008 Dec; 15(6):813-28. Philippar U, Roussos ET, Oser M, Yamaguchi H, Kim HD, Giampieri S, Wang Y, Goswami S, Wyckoff JB, Lauffenburger DA, Sahai E, Condeelis JS, Gertler FB. PMID: 19081071.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansAnimalsCells
    21. Genetic analysis of the diabetes-prone C57BLKS/J mouse strain reveals genetic contribution from multiple strains. Biochim Biophys Acta. 2006 Apr; 1762(4):440-6. Mao HZ, Roussos ET, Péterfy M. PMID: 16481151.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCells
    22. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003 Mar; 9(3):1136-44. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, Berenson JR. PMID: 12631619.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCells
    23. Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma. Cancer Genet Cytogenet. 2002 Aug; 137(1):43-8. Parker KM, Ma MH, Manyak S, Altamirano CV, Tang YM, Frantzen M, Mikail A, Roussos E, Sjak-Shie N, Vescio RA, Berenson JR. PMID: 12377412.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    Evanthia's Networks
    Concepts (134)
    Derived automatically from this person's publications.
    Co-Authors (4)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department